FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer

For more information, read the FDA announcement and the Daiichi Sankyo press release.

For more information, read the FDA announcement and the Daiichi Sankyo press release.

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington